HomeIndustryTheseus Pharmaceuticals Inc. (THRX) Stock offers help to cash-strapped investors

Theseus Pharmaceuticals Inc. (THRX) Stock offers help to cash-strapped investors

Needham raised the price target for the Theseus Pharmaceuticals Inc. (NASDAQ:THRX) stock to “a Buy”. The rating was released on December 14, 2022, according to finviz. The research report from Wedbush has initiated the stock to Outperform, with a price target set at $24. The stock was initiated by SVB Leerink, who disclosed in a research note on November 01, 2021, to Outperform and set the price objective to $28. In their research brief published November 01, 2021, Jefferies analysts initiated the Theseus Pharmaceuticals Inc. stock to Buy with a price target of $23.

The latest trade, Performances and Moving Averages give us the following Picture

The share price of Theseus Pharmaceuticals Inc. (NASDAQ:THRX) dipped -0.45% to close Monday’s market session at $11.00, lower as compared to yesterday’s close. The stock price fluctuated between $10.31 and $11.56 throughout the trading session with the volume trading being 2553528 shares, which represented a significant variation when compared to the three months average volume of 181.22K shares. The firm’s stock price fluctuated 14.58% within the last five trades and 104.08% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price increased 67.17% in the last 6 months and 85.19% was added to its value over the previous 3 months. THRX stock is trading at a margin of 43.54%, 61.85% and 54.40% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…

Sponsored

As of the close of trading, THRX deals in the Healthcare domain. The stock is trading -27.68 percent below its 52-week high and 174.31 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is -23.5. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.

What Does Theseus Pharmaceuticals Inc.’s Profitability and Valuation Ratios Tell Us About the Stock?

The stock’s market cap achieved a total value of $454.30 million as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. The firm managed a Price-to-Book ratio of 1.94, which equates the market value of a stock with its book value.

Is Insider Trading a Real Thing?

Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 0.90 percent of Theseus Pharmaceuticals Inc. shares are owned by insiders, and 89.50 percent are held by financial institutions. HAYDEN DONALD J JR, the Director at Theseus Pharmaceuticals Inc. (THRX) has bought 9,900 shares of firm on Dec 30 at a price of $5.00 against the total amount of $49489.0. In another inside trade, HAYDEN DONALD J JR, Director of Theseus Pharmaceuticals Inc. (NASDAQ:THRX) bought 100 shares of the firm on Dec 29 for a total worth of $500.0 at a price of $5.00. An inside trade which took place on Dec 29, 10% Owner of Theseus Pharmaceuticals Inc. Foresite Capital Management V, bought 500,000 shares of firm against total price of $2.5 million at the cost of $5.00 per share.

RELATED ARTICLES

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Recent Post